drugset / Trial / NCT07570810
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
RandomizedParallel-groupTriple-blindTreatment
Summary
This is an exploratory study evaluating CS0159 in combination with Semaglutide in metabolic dysfunction-associated fatty liver disease (MAFLD) patients with obesity and type 2 diabetes (T2DM).
Timeline
- Start
- 2026-06-01
- Primary completion
- 2026-11-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CS0159 | Unknown | 4 mg | Oral |
| Comparator | Semaglutide | Peptide | 0.5 mg | Subcutaneous |